Pancreatic Neuroendocrine tumors and carcinomas (pNET) see the last year their incidence and prevalence going up. On the basis of their grade of differentiation and proliferation ratio measured Ki67 staining, there are divided into 3 grade groups : Grade 1 with Ki67 between 1 and 3%, Grade 2 between 3 and 20% and well-differentiated neuroendocrine grade tumors 3 with KI67 greater than 20%, so undifferentiated carcinomas.

pNET is a heterogenous group of tumors with variable prognosis. The aim of this study is to identify the prognostic factors in this population, as well the place of neutrophil-to-lymphocyte ratio as a prognostic marker. The primary endpoint is the description of clinic and pathological parameters of patients from Alsace. The secondary endpoints are the identification of prognostic factors in this population

Inclusion criteria:

1. Major topic ((≥18 years)
2. Subject with histologically confirmed pancreatic neuroendocrine tumor or carcinoma
3. Subject with tumours or neuroendocrine carcinoma of the pancreas at any stage of the disease.
4. Subject covered in one of the participating centres between 01/01/2008 and 01/01/2019
5. Have a pre-therapeutic biological check-up
6. Subject who has not expressed opposition to the use of his or her data for research purposes

Exclusion criteria:

1. Subject who expressed opposition to participate in the study
2. Lack of histological data
3. Minor subject
4. Patient under the protection of justice
5. Subject under guardianship or trusteeship

Subject with histologically confirmed pancreatic neuroendocrine tumor or carcinoma, with tumours or neuroendocrine carcinoma of the pancreas at any stage of the disease and covered in one of the participating centres between 01/01/2008 and 01/01/2019